These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26231707)

  • 1. Fragment-Based De Novo Design of Cyclin-Dependent Kinase 2 Inhibitors.
    Tripathi SK; Singh P; Singh SK
    Methods Mol Biol; 2016; 1336():47-58. PubMed ID: 26231707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein-Protein Interaction for the De Novo Design of Cyclin-Dependent Kinase Peptide Inhibitors.
    Arumugasamy K; Tripathi SK; Singh P; Singh SK
    Methods Mol Biol; 2016; 1336():59-66. PubMed ID: 26231708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
    Schneider G; Geppert T; Hartenfeller M; Reisen F; Klenner A; Reutlinger M; Hähnke V; Hiss JA; Zettl H; Keppner S; Spänkuch B; Schneider P
    Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach.
    Tripathi SK; Singh SK; Singh P; Chellaperumal P; Reddy KK; Selvaraj C
    J Mol Recognit; 2012 Oct; 25(10):504-12. PubMed ID: 22996593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E-novo: an automated workflow for efficient structure-based lead optimization.
    Pearce BC; Langley DR; Kang J; Huang H; Kulkarni A
    J Chem Inf Model; 2009 Jul; 49(7):1797-809. PubMed ID: 19552372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
    Dixon-Clarke SE; Shehata SN; Krojer T; Sharpe TD; von Delft F; Sakamoto K; Bullock AN
    Biochem J; 2017 Feb; 474(5):699-713. PubMed ID: 28057719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity.
    Choi SJ; Lee JE; Jeong SY; Im I; Lee SD; Lee EJ; Lee SK; Kwon SM; Ahn SG; Yoon JH; Han SY; Kim JI; Kim YC
    J Med Chem; 2010 May; 53(9):3696-706. PubMed ID: 20361800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
    Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
    J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
    Braña MF; Cacho M; García ML; Mayoral EP; López B; de Pascual-Teresa B; Ramos A; Acero N; Llinares F; Muñoz-Mingarro D; Lozach O; Meijer L
    J Med Chem; 2005 Nov; 48(22):6843-54. PubMed ID: 16250643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.
    Keenan SM; Welsh WJ
    J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of interactions and volume variation in discriminating active and inactive forms of cyclin-dependent kinase-2 inhibitor complexes.
    Saranya N; Selvaraj S
    Chem Biol Drug Des; 2011 Sep; 78(3):361-9. PubMed ID: 21599856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
    Pratt DJ; Bentley J; Jewsbury P; Boyle FT; Endicott JA; Noble ME
    J Med Chem; 2006 Sep; 49(18):5470-7. PubMed ID: 16942020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors.
    Duca JS
    Future Med Chem; 2009 Nov; 1(8):1453-66. PubMed ID: 21426059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.
    Noble ME; Endicott JA
    Pharmacol Ther; 1999; 82(2-3):269-78. PubMed ID: 10454204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computer-based de novo design of drug-like molecules.
    Schneider G; Fechner U
    Nat Rev Drug Discov; 2005 Aug; 4(8):649-63. PubMed ID: 16056391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonlinear scoring functions for similarity-based ligand docking and binding affinity prediction.
    Brylinski M
    J Chem Inf Model; 2013 Nov; 53(11):3097-112. PubMed ID: 24171431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.